Tag: Kedrion Biopharma

Kedrion SpA (“Kedrion”) is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, Primary Immune Deficiency and Rh sensitization which can lead to hemolytic disease of the fetus and newborn.
Kedrion Biopharma Inc. (“Kedrion Biopharma”), the US subsidiary of Kedrion, is headquartered in Fort Lee, New Jersey.

Rostec, Pharmstandard and Kedrion established a joint venture

The National Immunobiological Company (part of Rostec State Corporation), Pharmstandard and Kedrion Biopharma (Italy) signed an agreement to establish Kirov Plasma, a joint-stock company. The company ...

Joint program on the plasma products manufacturing in the Russian Federation

The leading Russian pharmaceutical holding companies “National Immunobiological Company” (affiliated to the State Corporation Rostec) and PAO “Pharmstandart”, and Kedrion Biopharma, one of the major f...